About Silence Therapeutics
Silence Therapeutics is a company based in London (United Kingdom) founded in 1999.. The company has 116 employees as of December 31, 2024. Silence Therapeutics has completed 1 acquisition, including Intradigm Corporation. Silence Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 116 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Silence Therapeutics, Plc.
-
Annual Revenue
$42.35 M30.7as on Dec 31, 2024
-
Net Profit
$-44.36 M20.12as on Dec 31, 2024
-
EBITDA
$-47.96 M9.6as on Dec 31, 2024
-
Latest Funding Round
$120 M (USD), Post-IPO
May 25, 2021
-
Investors
Astrazeneca
& 5 more
-
Employee Count
116
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Silence Therapeutics
Silence Therapeutics is a publicly listed company on the OTC with ticker symbol SLNCF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Silence Therapeutics
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $120.0M
-
First Round
First Round
(16 Dec 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Post-IPO - Silence Therapeutics | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Silence Therapeutics | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Silence Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Silence Therapeutics
Silence Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Mallinckrodt Pharmaceuticals and Adage Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Private equity firm focused on company buyouts
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Silence Therapeutics
Silence Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intradigm Corporation. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops RNA interference (RNAi) therapeutics for the treatment of cancer.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Silence Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Silence Therapeutics Comparisons
Competitors of Silence Therapeutics
Silence Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Silence Therapeutics
Frequently Asked Questions about Silence Therapeutics
When was Silence Therapeutics founded?
Silence Therapeutics was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Where is Silence Therapeutics located?
Silence Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
How many employees does Silence Therapeutics have?
As of Dec 31, 2024, the latest employee count at Silence Therapeutics is 116.
What is the annual revenue of Silence Therapeutics?
Annual revenue of Silence Therapeutics is $42.35M as on Dec 31, 2024.
What does Silence Therapeutics do?
Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.
Who are the top competitors of Silence Therapeutics?
Silence Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Is Silence Therapeutics publicly traded?
Yes, Silence Therapeutics is publicly traded on OTC under the ticker symbol SLNCF.
How many acquisitions has Silence Therapeutics made?
Silence Therapeutics has made 1 acquisition, including Intradigm Corporation.
Who are Silence Therapeutics's investors?
Silence Therapeutics has 6 investors. Key investors include Astrazeneca, Mallinckrodt Pharmaceuticals, Adage Capital Management, BVF Partners, and Consonance Capital.
What is Silence Therapeutics's ticker symbol?
The ticker symbol of Silence Therapeutics is SLNCF on OTC.